ReviewClinics in laboratory medicine2020
Measuring the Serologic Response to Severe Acute Respiratory Syndrome Coronavirus 2: Methods and Meaning.
Review in Clinics in laboratory medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Antibody Responses to SARS-CoV-2 and Common HCoVs in Hemodialysis Patients and Transplant Recipients: Data from the Dominican Republic.Vaccines · 2025Article
- Emerging Trends of Gold Nanostructures for Point-of-Care Biosensor-Based Detection of COVID-19.Molecular biotechnology · 2025Review
- Antibody Response to SARS-CoV-2 Vaccines in Transplant Recipients and Hemodialysis Patients: Data from the Dominican Republic.Vaccines · 2024Article
- Electrochemical Determination of Interaction between SARS-CoV-2 Spike Protein and Specific Antibodies.International journal of molecular sciences · 2022Article
- Performance Evaluation of Lateral Flow Assays for Coronavirus Disease-19 Serology.Clinics in laboratory medicine · 2022Review
- Biosensors for the Determination of SARS-CoV-2 Virus and Diagnosis of COVID-19 Infection.International journal of molecular sciences · 2022Review
- Feasibility of SARS-CoV-2 Antibody Testing in Remote Outpatient Trials.Open forum infectious diseases · 2021Article
- Evaluation of serological lateral flow assays for severe acute respiratory syndrome coronavirus-2.BMC infectious diseases · 2021Article
- Affinity Sensors for the Diagnosis of COVID-19.Micromachines · 2021Review
- Lateral Flow Serodiagnosis in the Double-Antigen Sandwich Format: Theoretical Consideration and Confirmation of Advantages.Sensors (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The entire spectrum of diagnostic testing, from reagent supply to test performance, has been a major focus during the coronavirus disease 2019 (COVID-19) pandemic. The hope for serologic testing is that it will provide both epidemiologic information about seroprevalence as well as individual information about previous infection. This information is particularly helpful for high-risk individuals who may be outside of the viral shedding window, such as children with suspected multisystem inflammatory syndrome. It is not yet understood whether serologic testing can be interpreted in terms of protective immunity. These concerns must be addressed using highly sensitive and specific tests.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.